Here's something you might be interested in.
Ask a Hipster — Advice you didn't know you needed
Big Screen — Movie commentary
Blurt — Music's inside track
Booze News — San Diego spirits
Classical Music — Immortal beauty
Classifieds — Free and easy
Cover Stories — Front-page features
Drinks All Around — Bartenders' drink recipes
Excerpts — Literary and spiritual excerpts
Feast! — Food & drink reviews
Feature Stories — Local news & stories
Fishing Report — What’s getting hooked from ship and shore
From the Archives — Spotlight on the past
Golden Dreams — Talk of the town
The Gonzo Report — Making the musical scene, or at least reporting from it
Letters — Our inbox
Movies@Home — Local movie buffs share favorites
Movie Reviews — Our critics' picks and pans
Musician Interviews — Up close with local artists
Neighborhood News from Stringers — Hyperlocal news
News Ticker — News & politics
Obermeyer — San Diego politics illustrated
Outdoors — Weekly changes in flora and fauna
Overheard in San Diego — Eavesdropping illustrated
Poetry — The old and the new
Reader Travel — Travel section built by travelers
Reading — The hunt for intellectuals
Roam-O-Rama — SoCal's best hiking/biking trails
San Diego Beer — Inside San Diego suds
SD on the QT — Almost factual news
Sheep and Goats — Places of worship
Special Issues — The best of
Street Style — San Diego streets have style
Surf Diego — Real stories from those braving the waves
Theater — On stage in San Diego this week
Tin Fork — Silver spoon alternative
Under the Radar — Matt Potter's undercover work
Unforgettable — Long-ago San Diego
Unreal Estate — San Diego's priciest pads
Your Week — Daily event picks
Biotech Acadia stock getting wild ride
Its one drug getting second-guessed
From the Secret Visitors TV ad.
Stock of San Diego-based Acadia Pharmaceuticals enjoyed a bounceback today (Friday, April 27), riding up 7.67 percent to $16.28. On Wednesday, it had taken a 22 percent plunge after a report that the Food and Drug Administration will re-examine its only drug, Nuplazid, that treats hallucinations and delusions from psychoses tied to Parkinson’s disease.
Video:
Secret Visitors TV ad
Arcadia Pharmaceuticals ad for Parkinson's sufferers
CNN reported on April 25 that the previous week, the Food and Drug Administration commissioner Scott Gottlieb had told Congress that the agency would “take another look” at Nuplazid. That report generated the selloff. The drug has been scrutinized for reports of people dying after taking it
The company has a well-known TV ad discussing “secret visitors”— the hallucinations that half of Parkinson’s sufferers are said to suffer. Within the last 52 weeks, the stock has been as highs $41.20. It is now trading near its 52-week low of $14.51.
Here's something you might be interested in.
Biotech Acadia stock getting wild ride
Its one drug getting second-guessed
Biotech Acadia stock getting wild ride
Its one drug getting second-guessed
From the Secret Visitors TV ad.
Stock of San Diego-based Acadia Pharmaceuticals enjoyed a bounceback today (Friday, April 27), riding up 7.67 percent to $16.28. On Wednesday, it had taken a 22 percent plunge after a report that the Food and Drug Administration will re-examine its only drug, Nuplazid, that treats hallucinations and delusions from psychoses tied to Parkinson’s disease.
Video:
Secret Visitors TV ad
Arcadia Pharmaceuticals ad for Parkinson's sufferers
CNN reported on April 25 that the previous week, the Food and Drug Administration commissioner Scott Gottlieb had told Congress that the agency would “take another look” at Nuplazid. That report generated the selloff. The drug has been scrutinized for reports of people dying after taking it
The company has a well-known TV ad discussing “secret visitors”— the hallucinations that half of Parkinson’s sufferers are said to suffer. Within the last 52 weeks, the stock has been as highs $41.20. It is now trading near its 52-week low of $14.51.
Comments